keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis avonex

keyword
https://www.readbyqxmd.com/read/27849348/reconsidering-the-economic-value-of-multiple-sclerosis-therapies
#1
Tiffany Shih, Craig Wakeford, Dennis Meletiche, Jesse Sussell, Adrienne Chung, Yanmei Liu, Jin Joo Shim, Darius Lakdawalla
OBJECTIVES: To illustrate a more comprehensive view of value associated with medicines treating a highly severe illness and to apply these insights to estimate the costs and benefits of 3 treatments for multiple sclerosis (MS): Avonex, Tysabri, and Tecfidera. STUDY DESIGN: Retrospective study spanning 2002 to 2013. We used economic theory to derive the value of therapy to patients with MS and to individuals who face the risk of contracting MS in the future, under the alternative assumptions that therapies were fully insured or paid for out of pocket...
November 1, 2016: American Journal of Managed Care
https://www.readbyqxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#2
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27798157/cd40-mediated-nf-%C3%AE%C2%BAb-activation-in-b-cells-is-increased-in-multiple-sclerosis-and-modulated-by-therapeutics
#3
Ding Chen, Sara J Ireland, Gina Remington, Enrique Alvarez, Michael K Racke, Benjamin Greenberg, Elliot M Frohman, Nancy L Monson
CD40 interacts with CD40L and plays an essential role in immune regulation and homeostasis. Recent research findings, however, support a pathogenic role of CD40 in a number of autoimmune diseases. We previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients exhibited enhanced proliferation with CD40 stimulation compared with healthy donors. In this study, we used a multiparameter phosflow approach to analyze the phosphorylation status of NF-κB and three major MAPKs (P38, ERK, and JNK), the essential components of signaling pathways downstream of CD40 engagement in B cells from MS patients...
October 26, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27512709/quality-of-life-in-relapsing-remitting-multiple-sclerosis-patients-receiving-cinnovex-compared-with-avonex
#4
Nahid Hatam, Peivand Bastani, Rahil Sadat Shahtaheri
OBJECTIVE: There is an increasing recognition among clinicians and researchers that the impact of chronic illnesses and their treatments must be assessed in terms of their quality of life (QoL) in addition to more traditional measures of clinical outcomes. The aim of this study was to compare the QoL in patients with relapsing-remitting multiple sclerosis (RRMS) using Avonex or CinnoVex. METHODS: We conducted a cross-sectional study on one hundred patients with RRMS, fifty and fifty patients were being treated with Avonex (Biogen Idec, USA) and CinnoVex (CinnaGen, Iran), respectively...
July 2016: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/27306062/assessment-of-il-17a-il-10-and-tgf-beta1-serum-titers-in-rrms-patients-treated-with-avonex-possible-biomarkers-for-treatment-response
#5
Rodica Bălaşa, Smaranda Maier, Septimiu Voidăzan, Adina Huţanu, Zoltán Bajkó, Anca Moţăţăianu, Brindusa Tilea, Cristina Tiu
: Individual response to interferon beta (IFN-β) 1a treatment is heterogeneous in multiple sclerosis (MS). Our objective was to find a connection between serum levels of interleukin (IL)-10, IL-17 and transforming growth factor beta (TGF-β)1 in MS patients treated with IFN-β in order to identify the nonresponders (NR). MATERIAL AND METHODS: We included in the study 32 healthy subjects and 32 MS patients: 10 naive, 10 early treated and 12 late treated with INF-β1a...
June 15, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27053635/combining-clinical-and-magnetic-resonance-imaging-markers-enhances-prediction-of-12-year-disability-in-multiple-sclerosis
#6
Tomas Uher, Manuela Vaneckova, Lukas Sobisek, Michaela Tyblova, Zdenek Seidl, Jan Krasensky, Deepa Ramasamy, Robert Zivadinov, Eva Havrdova, Tomas Kalincik, Dana Horakova
BACKGROUND: Disease progression and treatment efficacy vary among individuals with multiple sclerosis. Reliable predictors of individual disease outcomes are lacking. OBJECTIVE: To examine the accuracy of the early prediction of 12-year disability outcomes using clinical and magnetic resonance imaging (MRI) parameters. METHODS: A total of 177 patients from the original Avonex-Steroids-Azathioprine study were included. Participants underwent 3-month clinical follow-ups...
April 6, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/27003945/the-edss-plus-an-improved-endpoint-for-disability-progression-in-secondary-progressive-multiple-sclerosis
#7
Diego Cadavid, Jeffrey A Cohen, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Havrdova, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg, Deborah Kinch, Sophia Lee, Shulian Shang, Daniel Mikol
BACKGROUND: The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a lack of meaningful measurement of short-distance ambulatory and upper-extremity function. OBJECTIVE: To present a rationale for a composite endpoint adding the timed 25-foot walk (T25FW) and 9-Hole Peg Test (9HPT) to EDSS for SPMS disability progression assessment...
March 22, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/26468869/increased-serum-brain-derived-neurotrophic-factor-in-multiple-sclerosis-patients-on-interferon-%C3%AE-and-its-impact-on-functional-abilities
#8
Masoud Mehrpour, Fahimeh H Akhoundi, Maryam Delgosha, Hosein Keyvani, Mohammad R Motamed, Behnam Sheibani, Alipasha Meysamie
OBJECTIVES: To investigate the potential role of disease-modifying therapies (DMTs) used to treat multiple sclerosis on inducing brain-derived neurotrophic factor (BDNF) production. METHODS: A total of 82 patients entered the study. Sixty (73%) patients were on DMTs (15 on Avonex, 13 on Rebif, 27 on Betaferon, 3 on Mitoxantrone, and 2 on IVIg), whereas 22 received no DMTs. The degree of neurological impairment was recorded using the expanded disability status scale (EDSS)...
October 2015: Neurologist
https://www.readbyqxmd.com/read/26436079/preliminary-study-on-patients-located-at-the-kashani-isfahan-hospital-with-multiple-sclerosis-between-the-years-2011-and-2013
#9
Zahra Tolou-Ghamari, Fereshteh Ashtari, Vahid Shaygannejad, Abbas-Ali Palizban
BACKGROUND: Multiple sclerosis (MS) is a multifactorial disease that could result from demyelination of the myelin sheath. The aim of this study is to investigate the demographic features and rank the immunomodulating drugs in patients with MS. MATERIALS AND METHODS: This study was conducted in the MS clinic of the Isfahan Kashani Hospital, from 22 May, 2011 to 18 March, 2013. The data analyses (n = 1067) were divided into two periods: (1) 2011/05/22 to 2012/03/18 denoted as P1 and (2) 2012/04/02 to 2013/03/18 denoted as P2...
2015: Advanced Biomedical Research
https://www.readbyqxmd.com/read/26384035/immunomodulators-and-immunosuppressants-for-relapsing-remitting-multiple-sclerosis-a-network-meta-analysis
#10
REVIEW
Irene Tramacere, Cinzia Del Giovane, Georgia Salanti, Roberto D'Amico, Graziella Filippini
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics. Although there is consensus that these therapies reduce the frequency of relapses, their relative benefit in delaying new relapses or disability worsening remains unclear due to the limited number of direct comparison trials. OBJECTIVES: To compare the benefit and acceptability of interferon beta-1b, interferon beta-1a (Avonex, Rebif), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine and immunoglobulins for the treatment of people with RRMS and to provide a ranking of these treatments according to their benefit and acceptability, defined as the proportion of participants who withdrew due to any adverse event...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26268445/development-of-interferon-beta-neutralising-antibodies-in-multiple-sclerosis-a-systematic-review-and-meta-analysis
#11
REVIEW
Karthik Govindappa, Jean Sathish, Kevin Park, Jamie Kirkham, Munir Pirmohamed
PURPOSE: Interferon beta (IFN-β) is the drug of choice for treatment of relapsing forms of multiple sclerosis and is known to reduce the frequency and severity of relapses. This systematic review determines the occurrence of neutralising antibodies (NAbs) against different formulations of IFN-β: IFN-β-1a Avonex™, IFN-β-1a Rebif™ and IFN-β-1b Betaferon/Betaseron™. METHODS: The databases used in the review included MEDLINE Ovid (from 1950 to March 2015), Embase Ovid (from 1980 to March 2015), CENTRAL on The Cochrane Library (2011, Issue 4) and ClinicalTrials...
November 2015: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26214805/adherence-to-disease-modifying-drugs-among-patients-with-multiple-sclerosis-in-germany-a-retrospective-cohort-study
#12
Kerstin Hansen, Katrin Schüssel, Marita Kieble, Johanna Werning, Martin Schulz, Robert Friis, Dieter Pöhlau, Norbert Schmitz, Joachim Kugler
BACKGROUND: Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels of medication adherence in order to reach acceptable outcomes. The objective of this study was to describe adherence to four disease modifying drugs (DMDs) among statutorily insured patients within two years following treatment initiation. These drugs were interferon beta-1a i.m. (Avonex), interferon beta-1a s.c. (Rebif), interferon beta-1b s.c. (Betaferon) and glatiramer acetate s...
2015: PloS One
https://www.readbyqxmd.com/read/26154767/interferon-beta-1a-avonex%C3%A2-as-a-treatment-option-for-untreated-patients-with-multiple-sclerosis-axiom-a-prospective-observational-study
#13
Christoph Kleinschnitz, Gabriele Niemczyk, Karin Rehberg-Weber, Colin Wernsdörfer
The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment gaps or switches are common. The Avonex as Treatment Option for Untreated MS Patients (AXIOM) trial assessed the efficacy of newly-initiated intramuscular interferon beta-1a (IM IFNb-1a) after a treatment-free interval, with particular consideration of the previous course of disease and therapy...
2015: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/25985851/the-effect-of-vitamin-a-supplementation-on-foxp3-and-tgf-%C3%AE-gene-expression-in-avonex-treated-multiple-sclerosis-patients
#14
RANDOMIZED CONTROLLED TRIAL
Ali Akbar Saboor-Yaraghi, Mohammad Hossein Harirchian, Niyaz Mohammadzadeh Honarvar, Sama Bitarafan, Mina Abdolahi, Feridoun Siassi, Eisa Salehi, Mohammad Ali Sahraian, Mohammad Reza Eshraghian, Tina Roostaei, Fariba Koohdani
Multiple sclerosis (MS) is an autoinflammatory condition of the central nervous system with impaired T helper (Th)17 and regulatory T cell (Treg) balance that is involved in disease immunopathogenesis. The vitamin A active metabolite, retinoic acid, can re-establish this imbalance through the modulation of gene expression of specific nuclear receptors including Forkhead box P3 (FoxP3). At present, few data exist on the impact of vitamin A supplementation on T cell balance. This study reports the results of a clinical trial, over a 6-month period, of 36 relapsing-remitting MS (RRMS) patients that received vitamin A (25,000 IU retinyl palmitate) or placebo (one capsule of placebo per day)...
July 2015: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/25907350/therapeutic-effect-of-avonex-rebif-and-betaferon-on-quality-of-life-in-multiple-sclerosis
#15
RANDOMIZED CONTROLLED TRIAL
Naghmeh Mokhber, Amir Azarpazhooh, Elias Orouji, Bita Khorram, Morteza Modares Gharavi, Sorayya Kakhi, Hoda Khallaghi, Mahmoud Reza Azarpazhooh
AIMS: The aim of this study was to evaluate the effect of various disease-modifying therapies (DMT) on quality of life in multiple sclerosis (MS). METHODS: This was a three-arm parallel study with balanced randomization in which 90 newly diagnosed, definite MS subjects referred to Ghaem Medical Center, Mashhad, Iran were enrolled between 2006 and 2009. Patients were randomly allocated into three DMT groups: Avonex, Rebif and Betaferon. Health-related quality of life was assessed in MS patients at baseline and 12 months after treatment with DMT using the MS Quality of Life-54 questionnaire...
October 2015: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/25891611/remarkable-response-of-seropositive-neuromyelitis-optica-to-rituximab-therapy-first-report-from-kingdom-of-bahrain
#16
I Alsharoqi
BACKGROUND: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system that causes severe optic neuritis and myelitis attacks. Humoral immunity seems to have a prominent role in the pathogenesis of the disease. Recently the nature and understanding of NMO have been revolutionized by two factors (1) the identification of both a NMO IgG as a sensitive and specific diagnostic marker and (2) the identification of both specific radiological and pathologic features of the disease...
November 2014: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/25891550/early-mri-activity-predicts-treatment-nonresponse-with-intramuscular-interferon-beta-1a-in-clinically-isolated-syndrome
#17
RANDOMIZED CONTROLLED TRIAL
R P Kinkel, J H Simon, P O'Connor, R Hyde, A Pace
OBJECTIVE: Determine whether MRI activity 6 months after treatment initiation in the Controlled High-Risk Subjects Avonex® Multiple Sclerosis Prevention Study (CHAMPS) predicted progression to clinically definite multiple sclerosis (CDMS) over the subsequent 30 months in intramuscular interferon beta-1a (IM IFNβ-1a)-treated patients vs placebo-treated patients. METHODS: CHAMPS patients were randomized to once-weekly IM IFNβ-1a 30 μg or placebo for up to 36 months...
November 2014: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/25801840/an-intricate-mechanism-of-action-of-avonex-in-relapsing-remitting-multiple-sclerosis-patients-variation-of-serum-titre-of-interleukin-17a-interleukin-10-and-transforming-growth-factor-%C3%AE
#18
Rodica Balasa, Smaranda Maier, Septimiu Voidazan, Adina Hutanu, Zoltan Bajko, Anca Motataianu
INTRODUCTION: The immunopathogenesis of multiple sclerosis (MS) is a main field of research, together with the mechanism of action of most immune therapies in this disease, such as interferon beta. Interleukin (IL)-17 is considered to play a central part in the initial immune cascade in MS, though there are numerous interactions between other cytokines that might explain the heterogeneity of disease evolution and treatment response. MATERIAL AND METHODS: We tested the serum levels of IL-17A, IL-10 and transforming growth factor (TGF-β) using the enzyme-linked immunosorbent assay method in three small groups of relapsing-remitting MS patients: 10 being naïve without treatment, 10 patients receiving Avonex treatment early in the MS evolution (≤ one year from the MS onset) and 12 MS patients who received Avonex later in the disease evolution...
2015: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/25741224/disease-related-determinants-of-quality-of-life-10-years-after-clinically-isolated-syndrome
#19
R Philip Kinkel, Genevieve Laforet, Xiaojun You
BACKGROUND: The main clinical determinants of quality of life (QOL) 5 years after clinically isolated syndrome (CIS) are Expanded Disability Status Scale (EDSS) score and conversion to clinically definite multiple sclerosis (CDMS). The aim of this study was to determine the demographic, clinical, and magnetic resonance imaging (MRI) factors associated with QOL 10 years after CIS. METHODS: Controlled High Risk Avonex® Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS) 10-year patients were assessed for CDMS, EDSS score, MRI T2 activity, brain parenchymal fraction, and patient-reported QOL...
January 2015: International Journal of MS Care
https://www.readbyqxmd.com/read/25721402/a-robust-type-i-interferon-gene-signature-from-blood-rna-defines-quantitative-but-not-qualitative-differences-between-three-major-ifn%C3%AE-drugs-in-the-treatment-of-multiple-sclerosis
#20
COMPARATIVE STUDY
Daniel Harari, Irit Orr, Ron Rotkopf, Sergio E Baranzini, Gideon Schreiber
We analysed gene expression microarray data from whole blood samples from 228 multiple sclerosis (MS) patients either untreated or treated with one of three alternative commonly used interferon beta (IFNβ) disease modifying drugs: Avonex (×1 weekly), Betaseron (every second day) or Rebif (×3 weekly). Patient injections were not timed to coordinate sample collections, thus providing a global transcriptomic profile for each population of patients studied. Three hundred and fifty one genes were significantly differentially expressed by at least one of the IFNβ drugs...
June 1, 2015: Human Molecular Genetics
keyword
keyword
19164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"